Alkermes Announces FDA Acceptance for Review of New Drug Application for ALKS 5461

[anonymous]

DM here. And yes. Yes I do.

for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard antidepressant therapies. ALKS 5461 is a fixed-dose combination of buprenorphine, a partial mu-opioid receptor agonist and kappa-opioid receptor antagonist, and samidorphan, a mu-opioid receptor antagonist.

Again it will be used as a very, very last resort and even then it will meet a lot of resistance. Sorry not sorry that this is gonna be hard to get doctors to prescribe

What’s a DM?

 

[anonymous]

Public information, moron.

So as a DM you get your company drug information off the internet. Brilliant!

Btw, is that where you get your management skills too?
http://howtomanagesalesreps101